Table 6. Matched Cohort Analysis: Multivariate Odds ratio of developing new cancer comparing those who developed a new cancer vs. matched cohort of autotransplant recipients who did not.

	Univariate			Multivariate
Variable	N	OR (95% CI)	P	OR (95% CI)	P
KPS: 90-100 vs 0-80%	456/280	1.37 (0.93-2.03)	0.11	----	>0.10
BMI:
Normal	172	1.00	0.004b	1.00	0.020b
Overweight	340	1.02 (0.63-1.66)	0.94	1.22 (0.73-2.06)	0.519
Obesity	254	1.85 (1.14-2.98)	0.012	1.94 (1.15-3.26)	0.005
Smoker: Yes vs No	374/385	1.59 (1.10-2.29)	0.013	1.45 (0.99-2.12)	0.055
Lines of pre transplant therapy: >1 vs 1	284/485	1.20 (0.93-1.55)	0.165	1.32 (0.99-1.74)	0.053
Radiation: Yes vs No	208/561	1.07 (0.72-1.59)	0.739	---	>0.10
Thalidomide: Yes vs No	230/539	0.74 (0.48-1.14)	0.174	---	>0.10
Bortezomib: Yes vs No	108/661	0.94 (0.48-1.82)	0.845	---	>0.10
Lenalidomide: Yes vs No	53/716	0.99 (0.47-2.11)	0.985	---	>0.10
VAD: Yes vs No	369/400	1.34 (0.89-2.01)	0.158	---	>0.10
MP: Yes vs No	71/698	0.66 (0.33-1.32)	0.237	---	>0.10
Any Drug: Yes vs No	672/97	0.68 (0.41-1.11)	0.119	---	>0.10
Conditioning Regimen:
Melphalan alone	623	1.00	0.596c	---	>0.10
TBI used	37	1.75 (0.74-4.14)	0.205
BU+CY	44	0.93 (0.41-2.09)	0.86
Others	72	0.96 (0.50-1.85)	0.9079

^aThalidomide and Lenalidomide were not included in the model for fitting “Any Drug” effect.

^b2d.f. test

^c3 d.f. test